相关实验视频
Updated: Jan 6, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
22.9K
抗血小板治疗和中枢神经系统血瘤:一个使用FAERS和vigiaccess数据库的真实数据的队列研究
Lei Wang1, Haixia Cai, Shujuan Zhao
1Department of Pharmacy, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, School of Clinical Medicine, Henan University, Zhengzhou, Henan, China.
International journal of surgery (London, England)
|September 10, 2025
概括
抗血小板治疗与中枢神经系统 (CNS) 血液瘤有关,阿司匹林和克洛皮多格雷尔显示出最强烈的关联. 结果有助于管理这些关键心血管药物患者的风险.
科学领域:
- 心血管医学 心血管医学
- 神经学 神经学
- 药物监督 药物监督 药物监督
背景情况:
- 抗血小板治疗对于治疗动脉样硬化心血管疾病至关重要.
- 使用抗血小板药物的中枢神经系统 (CNS) 血瘤的风险需要进一步描述.
研究的目的:
- 分析抗血小板药物与中枢神经系统血瘤之间的关联.
- 通过人口统计和时间模式来描述风险差异.
主要方法:
- 从FAERS和VigiAccess数据库中分析中枢神经系统血瘤不良事件报告.
- 不成比例分析 (ROR) 用于识别安全信号.
- 按年龄,性别和发病时间进行分层分析.
主要成果:
- 对于所有四种抗血小板药物 (阿司匹林,克洛皮多格雷尔,普拉苏格雷尔,蒂卡格雷尔) 的显著不成比例的信号.
- 阿司匹林和克洛皮多格雷尔显示出最强的关联 (ROR高达40.13).
- 最常见的是皮膜下血瘤;女性表现出更强烈的信号;观察到早期发病模式.
结论:
- 抗血小板治疗和中枢神经系统血液瘤之间存在显著的关联.
- 不同的模式因药物,患者人口统计学和发病时间而异.
- 这些发现支持改善抗血小板使用的风险分层和安全监测.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
Venous Thrombosis III: Interprofessional Care
254
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
254
Therapeutic Drug Monitoring: Affecting Factors
163
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
163
Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K

